NEW YORK (360Dx) – Akers Biosciences this week reported 2016 revenues of $3 million, up 40 percent from $2.1 million in 2015, driven by an 85 percent year-over-year increase in sales of its heparin allergy test.

The firm reported a net loss of $3.3 million, or $0.61 per share, down 65% from a loss of $9.3 million, or $1.81 per share, in 2015.

Its R&D expenses were $1.2 million, down 15 percent from $1.4 million in 2015, and its SG&A expenses were $5.1 million, down 22 percent from $6.5 million in the prior year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.